Q3 2025 Earnings Call Transcript November 14, 2025 MiNK Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.65, expectations were $-0.86. Operator: Good morning, and welcome to MiNK ...

Ubisoft was at one point working on a brand-new Splinter Cell game but opted to scrap it in favor of a project that bombed.

The hallmarks of Sjögren's disease are sicca symptoms and dysfunction of the salivary and lacrimal glands, Reed and ...

New research shows graying may reflect a protective process where damaged hair stem cells are cleared, lowering melanoma risk ...

The FDA’s Marty Makary and Vinay Prasad have laid out a path for CRISPR treatments on demand. An expert weighs in on what it ...

Therapeutic cancer vaccines have experienced a remarkable resurgence over the past decade, representing a paradigm shift in oncology toward harnessing the immune system's intrinsic ability to combat ...

Senescent fibroblasts are aging cells in connective tissue that no longer divide and protect against tumor development. Yet, these same cells can promote cancer growth in a laboratory setting.Until ...

Researchers have developed the first bioengineered human bone-marrow model to test CAR T-cell therapies for ­acute myeloid ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, ...

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...